MedPal AI (MPAL ) has launched what it describes as a UK-first: direct AI integration between a consumer health app and a regulated pharmacy, designed to guide users into personalised clinical pathways for health and weight management.
The company said the new functionality builds on the MedPal app update announced on 8 December 2025. MedPal’s AI now analyses aggregated user health data, including body mass index (BMI), to identify individuals who may benefit from clinically supervised weight management and glucagon-like peptide-1 (GLP-1) treatments, as well as other supplements or medicines available through its online MedPal Clinic.
MedPal said the system uses “intelligent targeting” to flag indicators such as slow or blocked metabolism, weight loss goals and hunger control concerns. Importantly, it only suggests a GLP-1 assessment pathway to users whose BMI qualifies them for clinical evaluation, which the company says supports responsible, targeted healthcare rather than broad advertising.
In addition, MedPal intends to extend this approach beyond weight management to cover all medications that can be prescribed and dispensed by MedPal Pharmacy. This includes men’s and women’s health treatments that an independent prescriber can prescribe under the UK’s Electronic Prescription Drug Guidance (ePDG) regulations.
MedPal said the enhancement is deployed through its AI backend, meaning no app update is required. Eligible users are directed to MedPal Clinic’s assessment page and receive a 30% introductory discount using the code MEDPALAPP.
Going forward, the company said MedPal Clinic can also become a user’s designated pharmacy for other private or NHS prescriptions, supported by its automated 24/7 distribution centre and nationwide delivery model.
MedPal Chief Executive Officer Jason Drummond said: "We believe that this is a UK-first and that no other pharmacy has this depth of AI integration with a health app. Our system doesn't just advertise health supplements and weight loss treatments; it understands each user's health profile and only connects those who clinically qualify with our GLP-1 prescribing services. This is the future of personalised healthcare, and MedPal is leading it."
View from Vox
This is a clear example of MedPal’s proposition in practice, using an app-led data funnel to drive users into regulated, clinically supervised pathways that can be fulfilled through its pharmacy operations. If eligibility controls and governance remain robust, the approach could improve conversion while staying on the right side of responsible marketing. The planned expansion into a wider set of prescriber-led categories also hints at a broader revenue opportunity.